Therapeutic Potential of Fecal Microbiota Therapy (FMT)
Deadline for manuscript submissions: closed (28 February 2021) | Viewed by 17105
Interests: bacterial communities; gut microbiota; health and disease
Special Issues, Collections and Topics in MDPI journals
Fecal microbiota therapy (FMT) represents a new therapeutic approach that involves the application of a solution of fecal material from a healthy donor into the gut of the receiver with the intention of restoring gut dysbiosis. The therapeutic potential of FMT has been explored in the treatment of a multitude of diseases, both gastrointestinal and extraintestinal. The route to delivering FMT may be very different (upper vs. lower GI tract) in dependence of the disease that we are treating with FMT. From a clinical point of view, FMT has been shown to be a very effective method in the treatment of recurrent C. difficile infection that represents the most common hospital-acquired infection. FMT is currently tested as a therapeutic option for multiple diseases beyond Clostridium difficile. An important area of interest for FMT is the treatment of inflammatory bowel disease (IBD). Recently, the first randomized controlled trials exploring the use of FMT for treatment of IBD were published. The results are promising, but many questions remain unanswered in terms of donor selection, preparation of FMT, and route of treatment (foregut, hindgut, or a combination). FMT appears to be a promising option to treat functional gastrointestinal disorders, especially irritable bowel syndrome (IBS). However, the results of randomized studies show contradictory results. Preliminary studies indicate a possible potential of FMT to treat chronic liver diseases such as alcoholic and non-alcoholic steatohepatitis (ASH, NASH), complication of liver cirrhosis or primary sclerosing cholangitis (PSC). Further possible indications include neuropsychiatric diseases, autoimmune diseases, obesity, metabolic syndrome, and other dysbiosis-associated diseases. The main limiting factors for the expansion of this method are the potential risk of infections or transfer of propensity for the development of chronic diseases by an unknown microbial agent. In summary, the restoration of gut microbiota by FMT holds promise that this method may be effective in the treatment of infectious, inflammatory, and functional disorders of gastrointestinal tract and non-gastrointestinal diseases.
On these grounds, in this Special Issue, we welcome research articles, case reposts, and short communications to present the recent advances in the fecal microbiota therapy.Prof. Dr. Peter C. Konturek
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- fecal microbiota therapy
- gut microbiota
- Clostridium difficile infection
- inflammatory bowel disease
- gastrointestinal disorders
- irritable bowel syndrome
- gastrointestinal diseases